Here’s what you should know.
1. The study examined the effects of the procedure in 63 patients. Patients either underwent the procedure with the EsophyX device or received high-dose proton-pump inhibitor therapy. After six months the PPI control group received the TIF procedure.
2. The study showed 83 percent of patients who underwent a TIF procedure eliminated regurgitation and all atypical symptoms. There were 70 percent of patients who discontinued PPI therapy and at the 36-month follow-up 87 percent saw healing of the reflux esophagitis.
More GI/endoscopy news:
FDA clears Pure-Vu System for intra-procedural colon cleaning: 3 notes
FDA approves STELARA for Crohn’s disease treatment: 5 notes
AGA objects to American Board of Internal Medicine’s certification proposals: 4 notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.